Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 4 (April)

1. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
   Mol Cell Endocrinol, 269(1): 26-33. [Abstract] [Full-text]
2. Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.
   Int J Cancer, 120(10): 2096-109. [Abstract] [Full-text]
3. Dose delivered from Varian's CBCT to patients receiving IMRT for prostate cancer.
   Phys Med Biol, 52(8): 2267-76. [Abstract] [Full-text]
4. A feasibility study of using conventional jaws to deliver IMRT plans in the treatment of prostate cancer.
   Phys Med Biol, 52(8): 2147-56. [Abstract] [Full-text]
5. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
   Prostate, 67(7): 782-9. [Abstract] [Full-text]
6. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
   Prostate, 67(7): 790-7. [Abstract] [Full-text]
7. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
   Prostate, 67(7): 774-81. [Abstract] [Full-text]
8. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
   Prostate, 67(7): 764-73. [Abstract] [Full-text]
9. Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostate.
   Prostate, 67(7): 757-63. [Abstract] [Full-text]
10. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer.
    Prostate, 67(7): 743-56. [Abstract] [Full-text]
11. Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer.
    Prostate, 67(7): 732-42. [Abstract] [Full-text]
12. Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun.
    Clin Chim Acta, 380(1): 145-50. [Abstract] [Full-text]
13. IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats.
    Prostate, 67(7): 701-13. [Abstract] [Full-text]
14. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Prostate, 67(7): 685-91. [Abstract] [Full-text]
15. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.
    Prostate, 67(7): 692-700. [Abstract] [Full-text]
16. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
    Prostate, 67(7): 722-31. [Abstract] [Full-text]
17. HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells.
    Prostate, 67(7): 714-21. [Abstract] [Full-text]
18. Detection of S100 protein from prostatic cancer patients using anti-S100 protein antibody immobilized on POS-PVA discs.
    Biotechnol Bioeng, 97(1): 182-7. [Abstract] [Full-text]
19. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
    J Natl Cancer Inst, 99(7): 526-32. [Abstract] [Full-text]
20. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model.
    Int J Cancer, 120(11): 2491-8. [Abstract] [Full-text]
21. Increased expression of estrogen-related receptor alpha (ERRalpha) is a negative prognostic predictor in human prostate cancer.
    Int J Cancer, 120(11): 2325-30. [Abstract] [Full-text]
22. A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland).
    Int J Cancer, 120(11): 2466-73. [Abstract] [Full-text]
23. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.
    Nature, 446(7136): 690-4. [Abstract] [Full-text]
24. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
    Am J Clin Oncol, 30(2): 199-204. [Abstract] [Full-text]
25. Imaging of prostate cancer.
    Curr Opin Oncol, 19(3): 259-64. [Abstract] [Full-text]
26. Bone metastases in prostate cancer: a targeted approach.
    Curr Opin Oncol, 19(3): 254-8. [Abstract] [Full-text]
27. Prostate cancer update: 2006.
    Curr Opin Oncol, 19(3): 229-33. [Abstract] [Full-text]
28. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer.
    Anticancer Drugs, 18(5): 563-8. [Abstract] [Full-text]
29. Evidence-based clinical practice guidelines for prostate cancer: the need for a unified approach.
    Curr Opin Urol, 17(3): 200-7. [Abstract] [Full-text]
30. Energy-based ablative therapy of prostate cancer: high-intensity focused ultrasound and cryoablation.
    Curr Opin Urol, 17(3): 194-9. [Abstract] [Full-text]
31. Neoadjuvant therapy and prostate cancer: what a urologist should know.
    Curr Opin Urol, 17(3): 188-93. [Abstract] [Full-text]
32. Novel targets and approaches in advanced prostate cancer.
    Curr Opin Urol, 17(3): 182-7. [Abstract] [Full-text]
33. Prostate cancer immunotherapy.
    Curr Opin Urol, 17(3): 175-81. [Abstract] [Full-text]
34. Dietary intervention in the management of prostate cancer.
    Curr Opin Urol, 17(3): 168-74. [Abstract] [Full-text]
35. Prostate cancer prevention.
    Curr Opin Urol, 17(3): 157-67. [Abstract] [Full-text]
36. Dietary intake and development of a quantitative food-frequency questionnaire for the Barbados National Cancer Study.
    Public Health Nutr, 10(5): 464-70. [Abstract] [Full-text]
37. beta-Alkylthio indolyl carbinols: potent nonsteroidal antiandrogens with oral efficacy in a prostate cancer model.
    Bioorg Med Chem Lett, 17(9): 2545-8. [Abstract] [Full-text]
38. IKKalpha at the crossroads of inflammation and metastasis.
    Cell, 129(1): 25-6. [Abstract] [Full-text]
39. Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines.
    Toxicol Appl Pharmacol, 220(2): 197-210. [Abstract] [Full-text]
40. First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.
    Bioorg Med Chem, 15(10): 3413-21. [Abstract] [Full-text]
41. KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer.
    Oncogene, 26(17): 2525-34. [Abstract] [Full-text]
42. Recto-urethral fistula following brachytherapy for localized prostate cancer.
    Colorectal Dis, 9(4): 328-31. [Abstract] [Full-text]
43. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
    J Urol, 177(5): 1913-7. [Abstract] [Full-text]
44. Identification of a recurrent t(4;6) chromosomal translocation in prostate cancer.
    J Urol, 177(5): 1907-12. [Abstract] [Full-text]
45. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite.
    J Urol, 177(5): 1856-61. [Abstract] [Full-text]
46. Prostate cancer knowledge among low income minority men.
    J Urol, 177(5): 1851-5. [Abstract] [Full-text]
47. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
    J Urol, 177(5): 1777-81. [Abstract] [Full-text]
48. Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis.
    J Urol, 177(5): 1771-5; discussion 1775-6. [Abstract] [Full-text]
49. Laparoscopic extraperitoneal radical prostatectomy in complex surgical cases.
    J Urol, 177(5): 1765-70. [Abstract] [Full-text]
50. Patterns of local failure following prostate brachytherapy.
    J Urol, 177(5): 1759-63; duscussion 1763-4. [Abstract] [Full-text]
51. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
    J Urol, 177(5): 1753-8. [Abstract] [Full-text]
52. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
    J Urol, 177(5): 1749-52. [Abstract] [Full-text]
53. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    J Urol, 177(5): 1745-8. [Abstract] [Full-text]
54. Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml.
    J Urol, 177(5): 1741-4. [Abstract] [Full-text]
55. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
    J Urol, 177(5): 1736-40. [Abstract] [Full-text]
56. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
    BJU Int, 99(5): 1150-3. [Abstract] [Full-text]
57. Robotic radical prostatectomy: outcomes of 500 cases.
    BJU Int, 99(5): 1109-12. [Abstract] [Full-text]
58. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
    BJU Int, 99(5): 1047-55. [Abstract] [Full-text]
59. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer.
    BJU Int, 99(5): 1041-6. [Abstract] [Full-text]
60. Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer.
    BJU Int, 99(5): 1036-40. [Abstract] [Full-text]
61. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin.
    Br J Cancer, 96(8): 1246-52. [Abstract] [Full-text]
62. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway.
    Biochemistry, 46(16): 4716-24. [Abstract] [Full-text]
63. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients.
    BJU Int, 99(5): 1056-65. [Abstract] [Full-text]
64. Fluctuating prostate-specific antigen levels in patients with initial negative biopsy: should we be reassured?
    BJU Int, 99(5): 1028-30. [Abstract] [Full-text]
65. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
    Hum Pathol, 38(5): 696-701. [Abstract] [Full-text]
66. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.
    BJU Int, 99(5): 1154-60. [Abstract] [Full-text]
67. The evidence-based pathway for peri-operative management of open and robotically assisted laparoscopic radical prostatectomy.
    BJU Int, 99(5): 1103-8. [Abstract] [Full-text]
68. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
    J Pharmacol Exp Ther, 321(2): 616-25. [Abstract] [Full-text]
69. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden.
    Int J Cancer, 120(12): 2678-86. [Abstract] [Full-text]
70. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
    BJU Int, 99(5): 1024-7. [Abstract] [Full-text]
71. Clinically localised prostate cancer is microsatellite stable.
    BJU Int, 99(5): 1031-5. [Abstract] [Full-text]
72. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    BJU Int, 99(5): 1066-71. [Abstract] [Full-text]
73. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation.
    Cancer Res, 67(8): 3845-52. [Abstract] [Full-text]
74. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
    Cancer Res, 67(8): 3818-26. [Abstract] [Full-text]
75. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells.
    Cancer Res, 67(8): 3663-72. [Abstract] [Full-text]
76. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
    Cancer Res, 67(8): 3646-53. [Abstract] [Full-text]
77. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.
    Cancer Res, 67(8): 3524-8. [Abstract] [Full-text]
78. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
    J Clin Oncol, 25(12): 1476-81. [Abstract] [Full-text]
79. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
    J Clin Oncol, 25(12): 1596-605. [Abstract] [Full-text]
80. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
    Mod Pathol, 20(5): 538-44. [Abstract] [Full-text]
81. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate.
    Oncogene, 26(18): 2667-73. [Abstract] [Full-text]
82. Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002.
    Med Care, 45(5): 440-7. [Abstract] [Full-text]
83. Treatment choice and quality of care for men with localized prostate cancer.
    Med Care, 45(5): 401-9. [Abstract] [Full-text]
84. Identification and characterization of the novel human prostate cancer-specific PC-1 gene promoter.
    Biochem Biophys Res Commun, 357(1): 8-13. [Abstract] [Full-text]
85. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(1): 24-33. [Abstract] [Full-text]
86. Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
    J Pept Sci, 13(5): 348-53. [Abstract] [Full-text]
87. Bayesian analysis of generalized odds-rate hazards models for survival data.
    Lifetime Data Anal, 13(2): 241-60. [Abstract] [Full-text]
88. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
    Eur J Cancer, 43(7): 1180-7. [Abstract] [Full-text]
89. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Int J Radiat Oncol Biol Phys, 68(1): 34-40. [Abstract] [Full-text]
90. Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(1): 41-9. [Abstract] [Full-text]
91. Secondary metabolites from Commiphora opobalsamum and their antiproliferative effect on human prostate cancer cells.
    Phytochemistry, 68(9): 1331-7. [Abstract] [Full-text]
92. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.
    J Immunother (1997), 30(4): 396-405. [Abstract] [Full-text]
93. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide.
    Biochem Biophys Res Commun, 357(2): 511-6. [Abstract] [Full-text]
94. The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.
    Biochem Biophys Res Commun, 357(2): 341-6. [Abstract] [Full-text]
95. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases.
    Am J Surg Pathol, 31(5): 697-705. [Abstract] [Full-text]
96. Penile metastasis from a T1b prostate carcinoma.
    Onkologie, 30(5): 249-52. [Abstract] [Full-text]
97. Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth.
    Mol Endocrinol, 21(5): 1039-48. [Abstract] [Full-text]
98. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
    Carcinogenesis, 28(5): 1032-9. [Abstract] [Full-text]
99. Characterization of androgen-regulated expression of CYP3A5 in human prostate.
    Carcinogenesis, 28(5): 916-21. [Abstract] [Full-text]
100. Regulation of survivin expression by IGF-1/mTOR signaling.
     Oncogene, 26(19): 2678-84. [Abstract] [Full-text]
101. Hypothesis: oxidative stress score as a combined measure of pro-oxidant and antioxidant exposures.
     Ann Epidemiol, 17(5): 394-9. [Abstract] [Full-text]
102. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis.
     Lancet Oncol, 8(5): 411-9. [Abstract] [Full-text]
103. Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.
     Prostate, 67(8): 900-6. [Abstract] [Full-text]
104. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy.
     Prostate, 67(8): 871-80. [Abstract] [Full-text]
105. Molecular PCA3 diagnostics on prostatic fluid.
     Prostate, 67(8): 881-7. [Abstract] [Full-text]
106. Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors.
     Prostate, 67(8): 855-62. [Abstract] [Full-text]
107. RNASEL Arg462Gln polymorphism and prostate cancer in PLCO.
     Prostate, 67(8): 849-54. [Abstract] [Full-text]
108. Nested case-control study of occupational chemical exposures and prostate cancer in aerospace and radiation workers.
     Am J Ind Med, 50(5): 383-90. [Abstract] [Full-text]
109. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
     Prostate, 67(8): 829-39. [Abstract] [Full-text]
110. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
     Prostate, 67(8): 799-807. [Abstract] [Full-text]
111. Mutational analysis of SPANX genes in families with X-linked prostate cancer.
     Prostate, 67(8): 820-8. [Abstract] [Full-text]
112. Characterization of the RSL1-dependent conditional expression system in LNCaP prostate cancer cells and development of a single vector format.
     Prostate, 67(8): 808-19. [Abstract] [Full-text]
113. Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.
     Int J Cancer, 121(1): 88-94. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.